[Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice]. - Archive ouverte HAL Access content directly
Journal Articles Revue medicale suisse Year : 2016

[Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].

(1) ,
1
Eloi Magnin
Julius Popp
  • Function : Author

Abstract

The cerebrospinal fluid levels of amyloid beta 1-42 (Aβ1-42), total tau and tau phosphorylated at threonine 181 (ptau181) are well established biomarkers of cerebral amyloid pathology and tau related neurodegeneration, two hallmarks of Alzheimer's disease. These biomarkers can help to improve diagnostic accuracy and consequent decisions on counseling, support, and therapy of patients with mild cognitive impairment and dementia. The use of biomarkers is part of the proposed new criteria of AD diagnosis. It may be particularly helpful in cases of atypical clinical presentation and uncertain diagnosis, and if an important benefit for the patient is expected. The ongoing development of new biomarkers based on less or non-invasive procedures will allow for a larger use of biomarkers to improve the diagnosis of cognitive impairment.
Not file

Dates and versions

hal-03630213 , version 1 (04-04-2022)

Identifiers

  • HAL Id : hal-03630213 , version 1
  • PUBMED : 27276722

Cite

Eloi Magnin, Julius Popp. [Cerebrospinal fluid biomarkers of Alzheimer's disease in current clinical practice].. Revue medicale suisse, 2016, 12 (515), pp.791-4. ⟨hal-03630213⟩

Collections

UNIV-FCOMTE
12 View
0 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More